IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Siemens Fonds Invest GmbH

Siemens Fonds Invest GmbH lessened its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 78.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 563 shares of the company’s stock after selling 2,103 shares during the quarter. Siemens Fonds Invest GmbH’s holdings in IDEXX Laboratories were worth $241,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the business. Sax Wealth Advisors LLC lifted its holdings in shares of IDEXX Laboratories by 76.3% during the fourth quarter. Sax Wealth Advisors LLC now owns 1,426 shares of the company’s stock worth $590,000 after purchasing an additional 617 shares during the period. Hantz Financial Services Inc. lifted its holdings in shares of IDEXX Laboratories by 11.5% during the fourth quarter. Hantz Financial Services Inc. now owns 7,738 shares of the company’s stock worth $3,199,000 after purchasing an additional 800 shares during the period. Paragon Capital Management Inc. lifted its holdings in shares of IDEXX Laboratories by 25.7% during the fourth quarter. Paragon Capital Management Inc. now owns 3,820 shares of the company’s stock worth $1,579,000 after purchasing an additional 782 shares during the period. Manitou Investment Management Ltd. lifted its holdings in IDEXX Laboratories by 491.0% in the fourth quarter. Manitou Investment Management Ltd. now owns 52,202 shares of the company’s stock valued at $21,582,000 after acquiring an additional 43,369 shares during the period. Finally, Fiera Capital Corp lifted its holdings in IDEXX Laboratories by 12.3% in the fourth quarter. Fiera Capital Corp now owns 141,198 shares of the company’s stock valued at $58,377,000 after acquiring an additional 15,463 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on IDXX. Bank of America boosted their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a report on Tuesday, February 4th. Stifel Nicolaus decreased their price target on IDEXX Laboratories from $450.00 to $420.00 and set a “hold” rating for the company in a report on Monday, April 14th. Barclays boosted their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Morgan Stanley boosted their price target on IDEXX Laboratories from $548.00 to $558.00 and gave the company an “overweight” rating in a report on Monday, May 5th. Finally, Piper Sandler boosted their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a report on Monday, February 10th. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $524.75.

IDEXX Laboratories Stock Up 1.2%

IDEXX Laboratories stock opened at $518.10 on Monday. The stock has a market capitalization of $41.67 billion, a PE ratio of 48.56, a price-to-earnings-growth ratio of 3.41 and a beta of 1.52. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $545.43. The business has a 50 day simple moving average of $431.28 and a 200-day simple moving average of $431.45. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Thursday, May 1st. The company reported $2.96 EPS for the quarter, beating analysts’ consensus estimates of $2.93 by $0.03. The business had revenue of $998.43 million during the quarter, compared to analysts’ expectations of $998.25 million. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The business’s revenue was up 3.6% compared to the same quarter last year. During the same period in the previous year, the business earned $2.71 earnings per share. On average, analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.